Dalbavancin as sequential therapy for infective endocarditis due to Gram-positive organisms: a review.

• Dalbavancin is a long-acting glycopepetide, approved for use in skin and soft tissue infections. • Limited data are currently available regarding the use of dalbavancin in deeper seated infections, such as infective endocarditis. • This article reviews the literature on the use of dalbavancin in infective endocarditis. • The data suggest that dalbavancin could be used as sequential treatment for infective endocarditis. Dalbavancin is a parenteral lipoglycopeptide antibiotic derived from teicoplanin, an analogue of vancomycin. It is mainly used for skin and soft tissue infections. The sustained half-life of approximately 14 days makes dalbavancin a novel option for potential use as sequential treatment in infections such as infective endocarditis, which require prolonged antibiotic courses. However, only a few studies have been reported in the literature, and the use of dalbavancin remains limited. This article is a review of the currently available literature using dalbavancin for the treatment of infective endocarditis due to Gram-positive organisms. Almost all patients received dalbavancin as sequential therapy following standard-of-care antibiotics. The overall clinical efficacy of dalbavancin was approximately 90%, and it appeared to be well tolerated. [ABSTRACT FROM AUTHOR]